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OBJECTIVE: To study the effect of low molecular weight heparin (LMWH) in the treatment of severe
acute pancreatitis (SAP).
METHODS: A total of 265 SAP patients were randomly divided into two groups: firstly, the conventional
treatment group (C group, n = 130; and secondly the conventional treatment plus the LMWH treatment
group (LT group, n = 135). The clinical parameters, laboratory parameters and computed tomography
(CT) score of pancreatic necrosis (CTSPN) in the two groups were compared.
RESULTS: On admission, all the clinical parameters, laboratory parameters and CTSPN in the two
groups were not significantly different (p > 0.05). However, after treatment, in LT group, the clinical pre-
sentation improvement rate and laboratory parameters improvement were significantly higher than those
in C group (p < 0.05–0.01), and the acute physiology and chronic health evaluation (APACHE) II score,
complication rate, mortality and mean hospital stay in LT group were obviously lower than those in 
C group (p < 0.05–0.01). The CT score in LT group was much lower than that in C group (p < 0.05). Two
weeks after treatment FBI decreased obviously in C group, but not in LT group, and no haemorrhagic
complications occurred.
CONCLUSIONS: LMWH can enhance the effect of conventional treatment for SAP, and can markedly
decrease the mortality of SAP. LMWH is a simple, safe, economic and effective method for treatment of
SAP. It is can be used in every hospital. [Asian J Surg 2009;32(2):89–94]
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Introduction
Severe acute pancreatitis (SAP) is a severe and frequently
lethal disorder which occurs suddenly and develops rapidly.
SAP is usually accompanied with systemic inflammatory
cascades and microcirculatory disturbance. Microcircula-
tory disturbance is a trigger factor in the development of
SAP, and plays a key role in the development of multiple
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organ dysfunction syndrome or multiple organ failure
(MODS/MOF), which result in high mortality of SAP.
Although the basic research of SAP has shown promising
advances, and the therapeutic methods have improved,
nowadays the mortality rate of SAP is still as high as 20–
40%.1–3 Therefore searching for a new therapeutic method
is still a hot point in the field of pancreatic surgery.
Low molecular weight heparin (LMWH) is known to
posses a special anti-thrombin activity which is stronger and
safer than unfrationated heparin. LMWH can reduce the
release of cytokines and inflammatory mediators, resulting
in an improvement of the microcirculation of pancreas. Our
experimental study provides evidence that LMWH can
decrease TNF-α production in serum, and block the initi-
ation of an inflammatory storm; LMWH decrease ET-1
leading to improvement of microcirculation system; and
has anti-thrombus effect to reduce the formation of
microthrombosis in pancreas. These findings demon-
strate the important therapeutic effect of LMWH in the
treatment of SAP.4
From August 1998 to February 2004, a prospective mul-
ticentre study on the treatment of SAP using conventional
therapy plus LMWH was performed in the Xiangya Hos-
pital, Central South University, Changsha; The 163 Central
Hospital, Changsha; The Second Affiliated Hospital, Nanhua




All the 265 patients with SAP in this series were diagnosed
clinically according to the diagnosis criteria of SAP approved
by the Chinese Association of Surgery in 1997.5 Patients that
were sensitive to LMWH, pregnant, breast-feeding, had
coagulation disorders, or those undergoing haemodialy-
sis, were excluded from this study. The etiology of these
patients included biliary diseases in 154 patients (58.1%),
alcoholism in 73 (27.5%), excessive eating in 28 (10.6%), and
undetermined causes in 10 (3.9%). The diagnosis of SAP
is acute pancreatitis (AP) complicated with the following
conditions: 1) organ dysfunction and/or pancreatic necro-
sis, abcesses or pseudocysts; 2) peritonitis and/or Gey-
Turer sign, Cullen sign; 3) blood calcium < 1.87 mmol/L
(7.5 mg/dL); (4) acute physiology and chronic health eval-
uation (APACHE) II score ≥ 8; (5) Balthazar computed
tomography (CT) score ≥ class II.
The 265 patients were randomly divided into a conven-
tional therapy group (C group) and conventional therapy
plus LMWH treatment group (LT group).
Conventional therapy group (n=130)
There were 72 males and 58 females with aged 7–72 years in
this group. The median age was 54 years old. On admission,
130 patients (100%) had severe abdominal pain, 105 (80.8%)
had nausea and/or vomiting, and 79 (60.8%) had fever.
Among the 130 patients, six (4.6%) were accompanied with
acute respiratory distress syndrome (ARDS), five (3.8%)
with shock, seven (5.3%) with acute renal failure (ARF),
three (2.3%) with mild upper gastrointestinal (GI) bleeding,
and one with diffuse intravascular clotting (DIC). Six
patients (4.6%) had failure of two or more organs. The
average APACHE II score in the 130 patients was 11.5 ± 3.4.
The LT group (n = 135) included 84 males and 51
females aged 9–75 years (the median age was 56 years old)
in this group. On admission, 135 patients (100%) had severe
abdominal pain, 113 (83.7%) had nausea and/or vomiting,
and 85 (63.0%) had fever. Among the 135 patients, 11 (8.1%)
were accompanied with ARDS, five (3.7%) with shock,
nine (6.7%) with acute renal failure, three (2.3%) with mild
upper gastrointestinal bleeding, and seven (5.2%) patients
had failure of two or more organs.
The average APACHE II score in the 135 patients was
11.6 ± 3.6. On admission, the clinical parameters and
APACHE II scores between the C group and the LT group
were not significantly different (p > 0.05).
Treatment protocol
C group
The treatment included management of shock, main-
tenance of the water and electrolytes balance; fasting 
gastrointestinal decompression; administration of pan-
creatic enzymes inhibitor (sandostatin), losec, antibiotics
(cephalosporins/metronidazole) and oral manganese 
sulfate; and symptomatolytic treatment.
LT group
The treatment included following the methods used in the
C group, plus administering LMWH at 100 μg/kg per day
by subcutaneous injection starting from the admission
day and continuing for 7 days. Nesobiliary drainage was
not used in the C and LT group.
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Operative indications
An operation should be performed when the following
are in evidence 1) Patients with clinical presentation of
biliary pancreatitis and with no change or had deteriora-
tion of symptoms within 24–48 hours after treatment; 2)
Patients whose clinical presentations deteriorated rapidly
24–48 hours after treatment; 3) Pancreatic necrosis accom-
panied with infection or pancreatic abscess formation; 4)




APACHE II scores, clinical presentation improvement
rate, operation rate, complication rate, occurrence rate 
of organ failure, in hospital mortality, curative rate, and
mean hospital stay in the two groups were observed and
compared.
Laboratory tests
The following parameters on admission, at 1 week, and at 
2 weeks after treatment were determined: white blood
cells (WBC), haematocrit (HCT), platelets, serum and
urine amylase (AMS), coagulation function, blood sugar,
serum calcium, hepatic function, renal function and
blood gas analysis.
CT scan scores6
The CT scores on admission, at 1 week, and at 2 weeks after
treatment were compared in the LT group (35 cases treated
at Xiangya Hospital) and the C group (30 cases treated at
Xiangya Hospital).
Statistical analysis
Data were analysed using the software package SPSS 
10 (SPS, Chicago, IL, USA). Results were expressed includ-
ing standard deviation (SD). The values were compared




One week and two weeks after treatment, improvement of
clinical symptoms occurred in 16 (53.3%) and 23 patients
(76.7%) in the LT group respectively, and in eight (26.7%)
and 15 patients (50.0%) in the C group respectively (p < 0.05
in all groups).
APACHE II scores
APACHE II scores in the LT and C groups were not signif-
icantly different on admission (11.6 ± 3.6 vs. 11.5 ± 3.4) or
1 week after treatment (10.4 ± 2.9 vs. 10.5 ± 2.3) (all values
of p > 0.05). However 2 weeks after treatment the APACHE
II score in the LT group (8.5 ± 1.8) was significantly lower
than that in the C group (9.6 ± 2.4) (p < 0.05).
CT scores
On admission the CT score in the LT group (5.4 ± 1.9) 
and the C group (5.0 ± 1.5) was not significantly different 
(p > 0.05), however 1 week and 2 weeks after treatment 
the CT score in the LT group (3.8 ± 2.2, 2.1 ± 1.0) was
significantly lower compared with that of the C group
(4.9 ± 2.4, 4.3 ± 2.6) (all values of p < 0.05).
Blood and urine AMS
The levels of blood and urine AMS between the two groups
were not significantly different on admission (p > 0.05).
However at 1 week and 2 weeks after treatment the levels
of blood and urine AMS in the LT group were signifi-
cantly lower than those in the C group (all values of 
p < 0.05) (Table 1).
Blood levels for prothrombin time (PT), fibrinogen (FBI),
kaolin partial thromboplastine time (KPTT) and platelet
(PLT)
On admission and 1 week and 2 weeks after treatment,
the blood levels of PT, KPTT and PLT between the two
groups were not significantly different (all values of
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Table 1. Levers of blood AMS (U/L) and urine AMS (U/L3484)
(x ± s)
Group Time point Blood AMS Urine AMS
C group On admission 3684 ± 895 5723 ± 993
7 DAT 3163 ± 864 4563 ± 862
14 DAT 1738 ± 346 2453 ± 473
LT group On admission 3629 ± 963 5677 ± 981
7 DAT 11934 ± 326* 3462 ± 656†
14 DAT 913 ± 281* 1893 ± 295†
Comparing with the time point of on admission of C group, *p < 0.05;
†p < 0.001; AMS = amylase; DAT = days after treatment.
p > 0.05). Two weeks after treatment, the level of blood FBI
in the C group decreased significantly, but in the LT
group, the blood FBI had no significant change (Table 2).
No coagulation disturbance occurred in either of the two
groups.
MODS/MOF
During the process of treatment, in the C group ARDS
occurred in 46 patients (35.4%), pancreatic encephalopa-
thy in (PE)7 13 (10.0%) and GI bleeding in six (4.6%).
Among those patients, 28 patients (21.5%) had failure of
two or more organs.
In the LT group, ARDS occurred in 17 patients (12.6%),
pancreatic encephalopathy in three (2.2%) and GI bleed-
ing in five (3.7%). Among those patients, 12 patients (8.9%)
had failure of two or more organs.
Organ failure,8 especially ARDS, occurred more often
in the C group and the successful treatment rate in the C
group was lower than that of the LT group (Table 3).
Other complications and the successful treatment rate
During the process of treatment, the occurrence rate of
pancreatic pseudocysts, peripancreatic abscesses, pancreatic
fistulas and intestinal fistulas in the LT group and the 
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Table 2. Blood levels of PT, PFBI, KPTT and PLT (x ± s)
Group Time point PT(sec) FBI(g/L) KPTT(sec) PLT(109/L)
C group On admission 15.0 ± 1.5 3.5 ± 0.7 35.7 ± 3.9 180 ± 27
7 DAT 15.0 ± 2.5 3.0 ± 0.6 39.7 ± 5.7 240 ± 32
14 DAT 15.0 ± 2.5 2.5 ± 0.5* 39.8 ± 5.9 292 ± 37
LT group On admission 15.0 ± 1.8 3.6 ± 0.9 36.5 ± 4.0 175 ± 19
7 DAT 15.0 ± 1.9 3.1 ± 0.7 36.5 ± 4.0 230 ± 28
14 DAT 16.0 ± 1.6 3.0 ± 0.6 39.8 ± 5.6 294 ± 49
Comparing with the time point of on admission of C group, *p < 0.001; DAT = days after treatment; PT = prothrombin time; FBI = fibrinogen;
KPTT = kaolin partial thromboplastine time; PLT = platelet.
Table 3. MOF occurrence rate





treatment treatment rate (%)
ARDS C 6 (4.6) > 0.05 46 (35.4) < 0.001 85.6 (45/52) > 0.05
LT 11 (8.1) 17 (12.6) 82.1 (23/28)
Shock C 7 (5.4) > 0.05 0 > 0.05 85.7 (6/7) > 0.05
LT 9 (6.7) 0 88.8 (8/9)
ARF C 7 (5.4) > 0.05 0 > 0.05 100 (9/9) > 0.05
LT 9 (6.7) 0 100 (7/7)
PE8 C 0 > 0.05 13 (10.0) < 0.01 53.8 (7/13) > 0.05
LT 0 3 (2.2) 66.7 (2/3)
GI bleeding C 3 (2.2) > 0.05 6 (4.6) > 0.05 100 (9/9) > 0.05
LT 3 (2.3) 5 (3.7) 100 (8/8)
DIC C 1 (8.0) > 0.05 0 > 0.05 0 > 0.05
LT 0 0 0
MODS/MOF C 6 (4.6) > 0.05 28 (21.5) < 0.01 32.8 (13/34) < 0.05
LT 7 (5.2) 12 (8.9) 68.4 (13/19)
ARDS = acute respiratory distress syndrome; ARF = acute renal failure; PE = pancreatic encephalopathy; GI bleeding = gastrointestinal bleeding;
DIC = diffuse intravascular clotting; MODS/MOF = multiple organ dysfunction syndrome/multiple organ failure.
C group was not significantly different (all values of 
p > 0.05). The successful treatment rate of such complica-
tions in the LT group and the C group was also not signif-
icantly different (all values of p > 0.05).
Operation rate
During the process of treatment, in the C group, 15 cases
were converted to undergo operations including necrotic
pancreatic tissue debridement plus abdominal irrigation
and drainage (PDAID) in eight cases (26.7%). In the 
LT group, six (20.0%) were converted to undergo opera-
tion, including PDAID in one case (3.3%) (all values of 
p < 0.05).
Curative rate and mortality
The curative rate in the C group (69.4%, 90/130) was signifi-
cantly lower than that in the LT group (89.6%, 121/135)
(p < 0.05). The mortality in the C group (30.6%, 40/130) was
significantly higher than that of the LT group (10.4%,
14/135). The deaths of all the patients in the two groups
were due to MOF.
Mean hospital stay days
The mean hospital stay in the C group was 43±11 days, and
in the LT group it was 30 ± 8 days (p < 0.01).
Discussion
Acute pancreatitis is a disease which has many etiologies.
Each etiology seems to affect the pancreatic acinar cells in
some way that results in premature activation and retention
of potent proteolytic enzymes. In the early stages of pancre-
atitis, macrophages, neutrophils, and endothelial cells are
activated. Proinflammatory cytokines are released and
inflammation factors are elevated during acute pancreatitis
and have been implicated in the progression of pancreatitis-
associated microvascular disturbance and haemorrhagic
necrosis. Ischemia reperfusion injury and tiny thrombus are
closely associated with pancreatic microcirculation distur-
bance,4 which causes further secretion of cytokines. The
released inflammatory mediators can induce local effects
and systemic complications1 which can finally result in
MOF.9 MOF is the main cause of death in patients with
SAP. In our series, all the deaths were due to MOF. So
attenuation of cytokines and improvement of microcircu-
lation of pancreasis are very important in the treatment
of SAP.
The pancreas is divided into lobules supplied by lobar
artery. The lobar artery is an end artery and is not divided
into branches. Obstruction of the artery will cause sublob-
ular ischemia and necrosis, so the pancreas is susceptible
to ischaemic insult. There is also increasing evidence of
pancreatic and systemic microvascular disturbances in the
pathogenesis of pancreatitis, including vasoconstriction,
shunting, inadequate perfusion, and increased blood vis-
cosity and coagulation, which is a key pathological process
in the development of SAP. These processes may be caused
or exacerbated by ischemia-reperfusion injury and the
development of oxygen-derived free radicals.10,11 So,
improvement of pancreatic and systemic microvascular
disturbance is very important in blocking the pathological
and clinical process of the development of pancreatitis. Our
experimental and clinical studies showed that LMWH
therapy can ameliorate the damage of the pancreas, lungs,
kidneys and brain in SAP, prevent SAP-mediated organ
damage by down-regulating the level of serum ET-I, and
suppressing the activity of NF-kB to down-regulate the
levels of TNF-α and IL-6. IL-6 is induced by IL-1, and
seems to correlate with the severity of the SAP, reduce the
formation of microthrombosis resulting in improvement
of the microcirculation of the pancreas, lung, kidney and
brain, and decrease the mortality in SAP.3 These studies
suggested that LMWH had an obvious effect on the treat-
ment of SAP in humans and rats. In this clinical study, 
we found that in the LT group the clinical presentation
improvement rate was significantly higher than that in the
C group; and the complications, operation rate, mortality
and mean hospital stays were obviously lower than those
of the C group. These results suggest that LMWH also
had a significant effect on the treatment of SAP clinically.
Leizorovicz et al12 did a study to compare the effect and
safety of LMWH and unfractionated heparin in the initial
treatment of deep venous thrombosis. The results indicated
that LMWH appears to have a higher benefit to risk ratio
than unfractionated heparin in the treatment of venous
thrombosis. In our study, the coagulation function of all the
patients in the LT group had no statistical difference before
and after LMWH treatment and no bleeding complications
occurred. Thus, some clinicians may even prefer to use
LMWH, since it is easier to administer and does not require
adjustment of the dose by laboratory analysis.
In conclusion, the addition of LMWH in the treatment
of SAP is a safe, simple, economic and effective method,
which can be widely used.
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